Column Group IV, LP
CIK 0001796354 Name as filed on the most recent filing
Filed as Column Group IV, LP (26)
73 transaction lines · from 26 filings · filed 2022-01-26 to 2026-02-09 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Eikon Therapeutics, Inc. 1 filings
- ISSUER NGM Biopharmaceuticals Inc 22 filings
- ISSUER Rapt Therapeutics, Inc. 3 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-02-06 |
Eikon Therapeutics, Inc. EIKN |
P, Open-market purchase | 1,437,323 acquired | 18.00 | 25,871,814.00 | Form 4, filing 0001193125-26-043320 | |
| 2026-02-06 |
Eikon Therapeutics, Inc. EIKN |
P, Open-market purchase | 630,881 acquired | 18.00 | 11,355,858.00 | Form 4, filing 0001193125-26-043320 | |
| 2026-02-06 |
Eikon Therapeutics, Inc. EIKN |
P, Open-market purchase | 49,556 acquired | 18.00 | 892,008.00 | Form 4, filing 0001193125-26-043320 | |
| 2023-11-16 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 5,840 acquired | 0.62 | 3,627.22 | Form 4, filing 0000950170-23-064854 | |
| 2023-11-15 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 16,791 acquired | 0.71 | 11,879.63 | Form 4, filing 0000950170-23-064854 | |
| 2023-01-31 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 176,730 acquired | 5.00 | 883,402.58 | Form 4, filing 0000899243-23-003137 | |
| 2023-01-30 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 7,542 acquired | 5.00 | 37,706.98 | Form 4, filing 0000899243-23-003137 | |
| 2023-01-23 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 9,900 acquired | 5.00 | 49,494.06 | Form 4, filing 0000899243-23-002637 | |
| 2023-01-20 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 500 acquired | 5.00 | 2,498.00 | Form 4, filing 0000899243-23-002380 | |
| 2023-01-19 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 37,639 acquired | 5.00 | 188,104.67 | Form 4, filing 0000899243-23-002380 | |
| 2023-01-12 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 5,378 acquired | 4.95 | 26,602.81 | Form 4, filing 0000899243-23-001855 | |
| 2023-01-11 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 209,000 acquired | 4.76 | 994,840.00 | Form 4, filing 0000899243-23-001695 | |
| 2023-01-10 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 100,070 acquired | 4.84 | 484,518.93 | Form 4, filing 0000899243-23-001695 | |
| 2022-12-12 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 300 acquired | 4.98 | 1,493.01 | Form 4, filing 0000899243-22-038466 | |
| 2022-11-22 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 4,330 acquired | 5.00 | 21,646.10 | Form 4, filing 0000899243-22-036916 | |
| 2022-11-21 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 35,997 acquired | 5.00 | 179,941.80 | Form 4, filing 0000899243-22-036916 | |
| 2022-11-04 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 35,058 acquired | 4.72 | 165,319.50 | Form 4, filing 0000899243-22-035277 | |
| 2022-11-03 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 104,090 acquired | 4.99 | 519,107.24 | Form 4, filing 0000899243-22-035277 | |
| 2022-10-27 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 76,877 acquired | 4.86 | 373,637.60 | Form 4, filing 0000899243-22-034562 | |
| 2022-10-26 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 72,774 acquired | 4.85 | 353,041.23 | Form 4, filing 0000899243-22-034359 | |
| 2022-10-25 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 51,046 acquired | 4.75 | 242,386.83 | Form 4, filing 0000899243-22-034359 | |
| 2022-06-09 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 951,684 acquired | 13.50 | 12,847,734.00 | Form 4, filing 0000899243-22-022214 | |
| 2022-06-09 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 32,477 acquired | 13.50 | 438,439.50 | Form 4, filing 0000899243-22-022214 | |
| 2022-06-02 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 33,071 acquired | 13.03 | 431,024.26 | Form 4, filing 0000899243-22-021216 | |
| 2022-06-02 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 1,129 acquired | 13.03 | 14,714.60 | Form 4, filing 0000899243-22-021216 | |
| 2022-06-01 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 88,964 acquired | 13.45 | 1,196,565.80 | Form 4, filing 0000899243-22-020690 | |
| 2022-06-01 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 3,036 acquired | 13.45 | 40,834.20 | Form 4, filing 0000899243-22-020690 | |
| 2022-05-31 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 59,766 acquired | 13.47 | 804,797.00 | Form 4, filing 0000899243-22-020690 | |
| 2022-05-31 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,040 acquired | 13.47 | 27,470.23 | Form 4, filing 0000899243-22-020690 | |
| 2022-05-27 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,621 acquired | 13.45 | 35,255.86 | Form 4, filing 0000899243-22-020203 | |
| 2022-05-27 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 89 acquired | 13.45 | 1,197.17 | Form 4, filing 0000899243-22-020203 | |
| 2022-05-26 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 19,534 acquired | 13.49 | 263,582.03 | Form 4, filing 0000899243-22-020203 | |
| 2022-05-26 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 667 acquired | 13.49 | 9,000.16 | Form 4, filing 0000899243-22-020203 | |
| 2022-05-25 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 1,837 acquired | 12.45 | 22,879.65 | Form 4, filing 0000899243-22-019940 | |
| 2022-05-25 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 63 acquired | 12.45 | 784.66 | Form 4, filing 0000899243-22-019940 | |
| 2022-05-25 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 41,863 acquired | 13.43 | 562,425.22 | Form 4, filing 0000899243-22-019690 | |
| 2022-05-25 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 1,429 acquired | 13.43 | 19,198.47 | Form 4, filing 0000899243-22-019690 | |
| 2022-05-24 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 17,240 acquired | 13.37 | 230,464.32 | Form 4, filing 0000899243-22-019690 | |
| 2022-05-24 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 588 acquired | 13.37 | 7,860.38 | Form 4, filing 0000899243-22-019690 | |
| 2022-05-24 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 15,776 acquired | 12.00 | 189,345.13 | Form 4, filing 0000899243-22-019471 | |
| 2022-05-24 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 538 acquired | 12.00 | 6,457.13 | Form 4, filing 0000899243-22-019471 | |
| 2022-05-23 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 9,898 acquired | 12.50 | 123,718.07 | Form 4, filing 0000899243-22-019471 | |
| 2022-05-23 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 338 acquired | 12.50 | 4,224.76 | Form 4, filing 0000899243-22-019471 | |
| 2022-05-20 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 18,406 acquired | 13.48 | 248,068.71 | Form 4, filing 0000899243-22-019209 | |
| 2022-05-20 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 628 acquired | 13.48 | 8,463.93 | Form 4, filing 0000899243-22-019209 | |
| 2022-05-19 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 19,984 acquired | 13.25 | 264,881.92 | Form 4, filing 0000899243-22-019209 | |
| 2022-05-19 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 682 acquired | 13.25 | 9,039.71 | Form 4, filing 0000899243-22-019209 | |
| 2022-05-18 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 60,583 acquired | 13.20 | 799,931.87 | Form 4, filing 0000899243-22-018849 | |
| 2022-05-18 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,067 acquired | 13.20 | 27,292.46 | Form 4, filing 0000899243-22-018849 | |
| 2022-05-17 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 86,110 acquired | 13.42 | 1,155,346.48 | Form 4, filing 0000899243-22-018849 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Column Group IV, LP, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001796354
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6